1Wakabayashi K,Takahashi H. Pathology of familial Parkinson' s disease[ J]. Brain Nerve,2007,59(8) :851-64.
2Kawahara K, Hashimoto M, Bar-On P, et al. alpha-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: Role in the pathogenesis of parkinson disease[ J]. Biol Chem,2008,283 ( 11 ) : 6979-6987.
3Marx FP, Soehn AS, Berg D, et al. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein-implications for Parkinson' s disease[J]. FASEB ,2007,21 (8) :1759-1767.
4Cookson MR. Parkin' s substrates and the pathways leading to neuronal damage [ J ]. Neummolecular Med,2003,3 ( 1 ) : 1-13.
5Vercammen L, Van der Perren A, Vaudano E, et al. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson' s disease [ J ]. Mol Ther, 2006,14 ( 5 ) : 716 -723.
6Poole AC, Thomas RE,Andrews LA, et al. The P1NK1/Parkin pathway regulates mitochondrial morphology [ J ]. Proc Natl Acad Sci USA,2008,105 ( 5 ) : 1638 -43.
7Hedrich K, Eskelson C, Wilmot B, et al. Distribution, type, and origin of Parkin mutations:review and case studies[ J]. Mov Disord,2004, 19(10) :1146-1157.
8Slominski PA, Miloserdova OV, Popova SN, et ah Analysis of deletion mutations in the PARK,2 gene in idiopathic Parkinson' s disease[ J]. Genetika, 2003,39 ( 2 ) : 223-228.
9Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, et al. Novel parkin mutations detected in patients with early-onset Parkinson' s disease [ J]. Mov Disord,2005,20(4) :424-431.
10Shadrina MI, Semenova EV, Slominsky PA, et al. Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1-12 dosage[ J]. BMC Med Genet,2007,8:6.
